Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Kevzara

- PMLiVE

NHS England launches hepatitis C screening scheme to reach 2030 elimination goal

The new scheme could help diagnose up to 80,000 people who do not know they have hepatitis C

- PMLiVE

ONS records a continued fall in UK COVID-19 infections

Latest figures have shown a drop in UK COVID-19 infections by more than half a million in a week

- PMLiVE

WHO launches funding appeal for greater Horn of Africa prompted by food crisis

The World Health Organization reported that over 80 million people in the seven countries in the region are estimated to be food insecure

- PMLiVE

Eli Lilly to make bebtelovimab commercially available to US states from August

The COVID-19 antibody is expected to become commercially available prior to the anticipated depletion of the US government’s current available supply

- PMLiVE

WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030

Globally only 52% of children living with HIV are on life-saving treatment, compared to 76% of adults receiving antiretrovirals

regeneron headquarters

Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV

The drug was taken off the US market in January due to it being ‘highly unlikely’ to be active against the Omicron variant

- PMLiVE

Moderna secures £1.74bn deal to supply US government with updated COVID-19 vaccine

The company will supply 66 million doses of its COVID-19 vaccine booster updated for the Omicron subvariant

- PMLiVE

Pfizer and BioNTech initiate phase 2 study of ‘enhanced’ COVID-19 vaccine

The vaccine is based on a version of the spike protein that the companies hope will offer better and broader protection against the virus

- PMLiVE

World Hepatitis Day highlights need to reach 2030 elimination target

According to the World Hepatitis Alliance, someone dies from a viral hepatitis-related illness every 30 seconds

- PMLiVE

Pfizer and BioNTech speak out against CureVac suit over patents for COVID-19 vaccines

The civil suit claims that once CureVac had withdrawn its vaccine candidate, the company was unable to garner 50% efficacy in a late-stage trial

- PMLiVE

Fauci addresses need for pan-coronavirus and intranasal vaccines to combat COVID-19 variants

Vaccine manufacturers have been urged to move forward with producing Omicron-targeting formulations

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links